AVIR Q1 2025 Earnings — Atea Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

AVIRAtea Pharmaceuticals, Inc.

$501M

Q1 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

-$3M

Operating Income

-$39M

Net Income

-$34M

EPS (Diluted)

$-0.40

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$31M

Free Cash Flow

-$31M

Stock-Based Comp.

$7M

Balance Sheet

Total Assets

$440M

Total Liabilities

$29M

Stockholders' Equity

$411M

Cash & Equivalents

$119M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	-$3M	-$104,000	-3207.7%
Operating Income	-$39M	-$70M	+44.1%
Net Income	-$34M	-$63M	+45.7%